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ABSTRACT 
Background. Inhaled corticosteroids (ICS) are the most widely prescribed and effective 
medication to control asthma symptoms and exacerbations. However, many children still have 
asthma exacerbations despite treatment, particularly in admixed populations, such as Puerto Ricans 
and African Americans. A few genome-wide association studies (GWAS) have been performed in 
European and Asian populations, and they have demonstrated the importance of the genetic 
component in ICS response.  
Objective. We aimed to identify genetic variants associated with asthma exacerbations in admixed 
children treated with ICS, and to validate previous GWAS findings. 
Methods. A meta-analysis of two GWAS of asthma exacerbations was performed in 1,347 
admixed children treated with ICS (Hispanics/Latinos and African Americans), analyzing 8.7 
million genetic variants. Those with p≤5x10-6 were followed up for replication in 1,697 asthmatic 
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patients from six European studies. Associations of ICS response described in published GWAS 
were followed up for replication in the admixed populations. 
Results. A total of 15 independent variants were suggestively associated with asthma exacerbations 
in admixed populations (p≤5x10-6). One of them, located in the intergenic region of APOBEC3B 
and APOBEC3C, showed evidence of replication in Europeans (rs5995653, p = 7.52x10
-3
) and was 
also associated with change in lung function after treatment with ICS (p = 4.91x10
-3
). Additionally, 
the reported association of the L3MBTL4-ARHGAP28 genomic region was confirmed in admixed 
populations, although a different variant was identified. 
Conclusions & Clinical Relevance. This study revealed the novel association of APOBEC3B and 
APOBEC3C with asthma exacerbations in children treated with ICS and replicated previously 
identified genomic regions. This contributes to the current knowledge about the multiple genetic 
markers determining responsiveness to ICS which could lead in the future the clinical identification 
of those asthma patients who are not able to respond to such treatment. 
Keywords: African American, childhood asthma, exacerbations, Latino, pharmacogenomics. 
INTRODUCTION 
Asthma is the most common chronic condition in children and young adults. In addition to the 
direct impact of the illness on the individual, severe exacerbations of asthma generate considerable 
economic costs to healthcare systems, as well as work and/or school absenteeism [1].  
Inhaled corticosteroids (ICS) are the most effective and commonly prescribed medications 
for symptom control and prevention of severe asthma exacerbations [1]. While most children using 
ICS experience a decrease in their asthma symptoms, 30-40% will continue to experience 
exacerbations, and of these non-responders, 10-15% may even have an increase in their 
exacerbations [2]. High variability in ICS response has been described also among ethnicities [3]. 
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In addition to high asthma morbidity, exacerbations rates and mortality, admixed populations have 
reduced ICS response [4]. These strong ethnic differences suggest a substantial hereditary 
component in the ICS response [5]. In fact, approximately 40-60% of the variation in ICS response 
may be due to genetic factors [6].  
For several decades, pharmacogenetic studies have utilized candidate-gene approaches, 
which only evaluate a small portion of the genetic variation. More recently, these have evolved 
towards hypothesis-free approaches by implementing genome-wide association studies (GWAS) 
[7]. Eight GWAS of ICS response have been performed to date [8-15], revealing an association 
between 14 genomic regions and this trait. 
However, the polymorphisms identified by GWAS to date only represent a small proportion 
of the heritability of ICS response, and hence it is not possible to predict an individual’s response to 
this treatment [16]. The design of the GWAS performed to date may be the main reason, where 
analyses are statistically underpowered to detect genetic associations. Most GWAS of ICS response 
have included a relatively small number of individuals (N<1,000) of primarily European and, to a 
lesser extent, Asian ancestry, with poor representation of admixed populations [4], which include 
Hispanics/Latinos and African Americans. However, the increased asthma prevalence among 
admixed individuals with African ancestry, such as Puerto Ricans and African Americans, and the 
greater genetic diversity and specific genetic background of these populations present a unique 
opportunity to study the response to ICS treatment in asthma [3-4]. 
We hypothesized that a large pharmacogenetic study of ICS response in admixed individuals 
with asthma that exhaustively explores the association of genetic variants across the genome could 
reveal novel genes associated with this trait. We also attempted to evaluate whether the associations 
described in GWAS performed in European and Asian populations could be generalized to 
admixed populations. 
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METHODS 
Study Populations 
A total of eight independent studies participating in the Pharmacogenomics in Childhood of 
Asthma (PiCA) consortium [17] were analyzed as part of discovery and replication phases of this 
meta-GWAS. Individuals from two admixed populations were included in the discovery phase: the 
Genes-environments & Admixture in Latino Americans Study (GALA II) and the Study of African 
Americans, Asthma, Genes and Environments (SAGE). Samples from six European PiCA studies 
were used for replication. All studies have been approved by their local institutional review boards 
and all participants/parents provided written informed assent and consent, respectively. GALA II 
and SAGE were approved by the Human Research Protection Program Institutional Review Board 
of the University of California, San Francisco (San Francisco, United States) (ethics approval 
numbers: 217802 and 210362, respectively). PACMAN was approved by the Medical Ethics 
Committee of the University Medical Centre Utrecht (Utrecht, the Netherlands). The Tayside 
Committee on Medical Research Ethics (Dundee, United Kingdom) approved BREATHE. PASS 
was approved by the Liverpool Paediatric Research Ethics Committee (Liverpool, United 
Kingdom) (reference number: 08/H1002/56). SLOVENIA was approved by the Slovenian National 
Medical Ethics Committee (Ljubljana, Slovenia). ESTATe was approved by the Medische Ethische 
Toetsings Commissie, Erasmus Medical Center (Rotterdam, the Netherlands) (ethics approval 
number: MEC-2011-474). followMAGICS was approved by the Ethik-Kommission der 
Bayerischen Landesärztekammer (Munich, Germany) (ethics reference number: 01218). 
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Discovery phase 
Patients from the GALA II and SAGE studies with a physician diagnosis of asthma who 
reported having active symptoms and asthma medication use within the last year were analyzed in 
the discovery phase. These are two independent studies focused on two different racial/ethnic 
groups based on the self-identified ethnicity of the four grandparents of each subject: 
Hispanics/Latinos (GALA II) and African Americans (SAGE). Both studies recruited unrelated 
children and young adults, aged 8 to 21 years old, using the same protocol and questionnaires from 
different areas in the United States. GALA II also recruited individuals in Puerto Rico [18]. 
Analyses were performed for a subset of 854 subjects from GALA II and 493 individuals 
from SAGE. Specifically, we assessed self-reported ICS use, age, gender, genome-wide genotypic 
data [19-20], and information regarding presence or absence of severe asthma exacerbations, as 
defined by the European Respiratory Society (ERS) and the American Thoracic Society (ATS) 
[21]. We examined exacerbations that occurred during the 12 months preceding the study 
enrollment (need to seek emergency asthma care, hospitalizations or the administration of oral 
corticosteroids).  
Replication phase 
Validation was carried out in European individuals from six independent studies participating 
in the PiCA consortium: the follow-up stage of the Multicenter Asthma Genetics in Childhood 
Study (followMAGICS); the Pharmacogenetics of Adrenal Suppression study (PASS); 
Pharmacogenetics of Asthma Medication in Children: Medication with Anti-inflammatory effects 
(PACMAN); Effectiveness and Safety of Treatment with Asthma Therapy in Children (ESTATe); 
BREATHE and SLOVENIA studies. Details for each study are described in the Supporting 
Information. 
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The use of ICS and availability of data related to the presence/absence of asthma 
exacerbations during the previous 12 or 6 months were also applied as inclusion criteria for the 
individuals from these studies analyzed in the current study, whereas non-availability of data 
related to ICS use, asthma exacerbations, age, gender and genotype data were considered as 
exclusion criteria. For those studies without data related to the events included in the ATS/ERS 
definition of asthma exacerbations, information regarding school absences, unscheduled general 
practitioner (GP) or respiratory system specialist visits was also considered. 
Genome-wide genotyping, genetic ancestry assessment and imputation 
Both GALA II and SAGE samples were genotyped using the Axiom® LAT1 array 
(Affymetrix Inc.), and quality control (QC) procedures were performed as described elsewhere [19-
20]. Genotyping of the subjects included in the replication phase was performed on different 
genotyping platforms, as described in previous publications (see Supporting Information) (Table 
S1). In addition, four of the studies were genotyped for the purposes of the PiCA consortium and 
their QC is described in the Supporting Information. 
Genetic ancestry was assessed by means of Principal Component (PC) analysis with 
EIGENSOFT 6.14 for the studies included in both discovery and replication phases [22]. 
Quantitative global genetic ancestry estimates were also obtained for the populations included in 
the discovery phase. An unsupervised model was applied using ADMIXTURE [23], assuming the 
European (CEU), African (YRI) and Native American (NAM) as the parental populations for the 
Hispanics/Latinos and YRI and CEU for African Americans. For that, reference haplotypes from 
CEU and YRI populations from the HapMap Project Phase III [24] were used. Moreover, 
haplotypes from individuals genotyped with Axiom® LAT1 array (Affymetrix Inc.) were 
considered as reference for NAM population, as described elsewhere [19, 25]. 
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In all the studies, imputation was carried out by means of the Michigan Imputation Server 
(https://imputationserver.sph.umich.edu) using the second release of the Haplotype Reference 
Consortium (HRC) (r1.1 2016) as reference panel [26]. Haplotype reconstruction and imputation 
were performed with SHAPEIT v2.r790 [27] and Minimac3 [28], respectively. 
Association testing and meta-analysis in the discovery phase 
GWAS analyses were carried out separately for GALA II and SAGE. Logistic regressions 
were used to evaluate the association between genetic variants and ICS response by means of the 
binary Wald test implemented in EPACTS 3.2.6 [29]. The presence or absence of any asthma 
exacerbations during the last 12 or 6 months in patients treated with ICS was considered as a 
measure of ICS response, which was evaluated as a binary variable. Age, gender, and the first two 
PCs, obtained with EIGENSOFT 6.14 [22], were included as covariates in the regression models. 
The number of PCs included as covariates was chosen based on the comparison of different models 
that included up to 10 PCs, showing that results based on 2 PCs had the best fit with the expected 
values under the null hypothesis of no association. 
Single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF)≥1% and with 
imputation quality (Rsq)≥0.3 in GALA II and SAGE, and shared among both populations were 
meta-analyzed using METASOFT [30]. Fixed-effects or random-effects models were selected for 
each variant depending on absence or presence of heterogeneity, respectively, which was assessed 
by means of the Cochran Q-test. A threshold of p-value≤5x10-6 was arbitrarily set to select variants 
suggestively associated with asthma exacerbations, since this threshold is commonly adopted in 
GWAS studies [31-35]. Among those variants, independent associations were detected by means of 
logistic regression analyses conditioned on the most significant SNP of each locus using R 3.4.3 
[36]. This analysis provided a list of independent variants that were followed up for replication.  
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Association testing and meta-analysis in the replication phase 
Statistical analyses were performed following the same methodology as in the discovery 
phase, except for the definition of asthma exacerbations available in each study and the number of 
PCs included as covariates in the association analyses (Table S1). Evidence of replication was 
considered for those SNPs that showed a combined p-value≤0.05 in a meta-analysis of all the 
European studies and consistent directions of effects in both discovery and validation populations. 
Association with ICS response measured as change in FEV1 
SNPs significantly associated with asthma exacerbations in both admixed and European 
populations, were evaluated for association with the change in the forced expiratory volume in 1 
second (FEV1) after 6 weeks of treatment with ICS in 166 ICS users from the SLOVENIA study, 
the only cohort included in the analyses with this outcome measured. This variable was 
dichotomized to define responders and non-responders to ICS treatment using a cutoff of ≥8% 
improvement of FEV1, which has been established as a good predictor of asthma severity in 
children [37]. Logistic regression models were applied including age, gender, and the first two PCs 
as covariates.  
Functional evaluation of variants associated with ICS response 
Functional annotation and evidence of significant expression quantitative trait loci (eQTL) 
were searched with HaploReg v4.1[38] based on data provided by the Encyclopedia of DNA 
Elements (ENCODE) project [39]. This was performed for the SNP associated with ICS response 
in admixed and European populations and those in high linkage disequilibrium (LD) (r
2
>0.9) 
according to African populations from the 1000 Genomes Project (1KGP) data incorporated by 
HaploReg v4.1. Gene expression was inspected using the Portal for the Genotype-Tissue 
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Expression (GTEx) [40] and the Gene Expression Atlas [41]. Moreover, evidence of association 
with enhancers was searched using the multiple sources available from GeneHancer [42]. 
Validation of previous associations in admixed populations  
Since previous GWAS of ICS response have focused on European and Asian populations [8-
15], we attempted to validate their results in admixed populations. A total of 25 SNPs near or 
within 14 genes declared as associated with ICS response [8-14],
 
were followed up for replication 
in GALA II and SAGE.  
Replication was attempted at the SNP level and also as genomic region, the latter considering 
variants located within 100 kilobases (kb) upstream or downstream from the gene where the variant 
was located or from the two closest genes in case the variant was intergenic. Evidence of 
replication was considered for SNPs nominally associated with ICS response (p≤0.05) that had the 
same direction of the effect as the published GWAS. For the replication at level of genomic region, 
a Bonferroni-like correction was applied to account for the number of independent variants tested 
within each genomic region, as estimated with empirical autocorrelations based on Markov Chain 
Monte Carlo (MCMC) simulations. For this, an autocorrelation matrix was obtained based on the -
log10 p-value of each SNP analyzed using the effectiveSize function from the R package coda [43], 
as described elsewhere [44]. According to this, a Bonferroni-corrected significance threshold was 
estimated for each genomic region with α=0.05/number of independent variants. 
RESULTS 
Characteristics of the study populations 
The characteristics of the 1,347 admixed asthmatic patients from GALA II and SAGE 
analyzed in the discovery phase and the 1,697 Europeans subjects included in the replication are 
shown in Table 1 and Table S1, respectively. In terms of estimates of global ancestry in the 
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admixed populations, Hispanics/Latinos had 13.6% African ancestry, 51.5% European ancestry and 
34.9% Native American ancestry. In contrast, African Americans had 79.4% African admixture 
and 20.6% European ancestry. Hispanics/Latinos reported a higher proportion of asthma 
exacerbations in the 12 months preceding study enrollment (66.4%) than African Americans 
(51.9%). Although asthma exacerbations were differentially defined in the validation populations, 
similar proportions were found across the discovery and replication studies, except for PACMAN 
and SLOVENIA, with values of 11.0% and 34.1%, respectively (Table S1). 
Discovery phase 
The meta-analysis of the GALA II and SAGE GWAS included 8.7 million SNPs that were 
shared among Hispanics/Latinos and African Americans and had MAF≥1% and Rsq≥0.3. The Q-Q 
plots of the association results for each individual study (Figure S1A and Figure S1B) and those 
obtained after combining both admixed populations did not reveal major genomic inflation due to 
population stratification (λGC = 1.04, Figure S1C). Although the genome-wide significant threshold 
(p-value≤5x10-8) was not reached by any of the variants, 27 SNPs with Rsq values ranging from 
0.59-1.00 and located near or within 13 loci were suggestively associated with asthma 
exacerbations despite the use of ICS (p-value≤5x10-6) in admixed children and young adults 
(Figure 1 and Table S2). 
After performing pairwise regression models conditioned on the most significant variant for 
each locus with at least two suggestive associations, one independent variant was detected per 
locus, except for APOBEC3B-APOBEC3C and ANKRD30B, where two SNPs remained significant 
after conditioning on each gene’s most significant variant (Table S3). As a result, 15 SNPs were 
identified as independently associated with ICS response in admixed populations (Table S3) and 
were followed up for replication.  
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Replication phase 
Of the 15 SNPs selected for replication in Europeans, 11 SNPs had a MAF≥1% and Rsq≥0.3 
(ranging from 0.36-1.00) in Europeans and were forwarded for replication (Table 2). Of those, 
rs5995653, located within the intergenic region of APOBEC3B and APOBEC3C (Figure 2), 
showed evidence of nominal replication after combining the European studies. To check that the 
association of this SNP in the admixed populations was not confounded by unaccounted 
components of ancestry, different regression models were tested including estimates of genetic 
ancestry, different number of PCs, or following the method described by Conomos et al. [45], 
which provided similar results (Table S4). The direction of effect for this SNP was the same in 
Europeans (OR for A allele: 0.76, 95% CI: 0.62-0.93, p = 7.52x10
-3
) as in the admixed samples 
(OR for A allele = 0.66, 95% CI: 0.56-0.79, p = 4.80x10
-6
) (Table 2). A meta-analysis of this SNP 
across the two phases resulted in a suggestive genome-wide significant association (OR for A allele 
= 0.70, 95% CI: 0.61-0.81, p = 3.31x10
-7
, Figure 3).  
Association of rs5995653 with ICS response measured as change in FEV1 
The SNP rs5995653 was significantly associated with a positive response to the ICS 
treatment in SLOVENIA, measured as an increase of FEV1 (OR for A allele = 2.16, 95% CI: 1.26-
3.70, p = 4.91x10
-3
), which is concordant with the protective effect of this SNP with asthma 
exacerbations in both discovery and validation studies.  
In silico functional role of the novel association detected 
The experimental data provided by the ENCODE project shows that the SNP rs5995653 is 
located within a histone H3 lysine 4 mono-methylation (H3K4me1) mark of an active gene 
enhancer and a DNAse hypersensitivity site in blood cells [39]. This is concordant with the 
GeneHancer evidence that APOBEC3B has been associated with enhancers that regulate multiple 
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transcription factor binding sites, indicating its involvement in the regulation of gene expression in 
different cell types, including lung fibroblasts [42]. Moreover, this variant is also in high LD with 
several eQTL in blood cells associated with the expression of APOBEC3A (rs9607601: p=1.80x10
-
13
 and rs5995654: p=9.10x10
-14
), APOBEC3G (rs9607601: p=0.003), and CBX6 (rs9607601: 
p=3.94x10
-4
 and rs5995654: p=4.00x10
-4
) [38-39, 46]. In addition, previous functional studies have 
evidenced high levels of gene expression of both APOBEC3B and APOBEC3C in pulmonary cells 
(GTEx) [40-41]. 
Validation of previous associations of ICS response 
None of the 25 SNPs previously associated with ICS response was consistently associated 
with asthma exacerbations in admixed populations (Table S5). To assess whether the lack of 
replication of previous GWAS hits could be due to the association of alternative genetic variants 
among different populations, a replication analysis was also performed at genomic region level. A 
total of 36,261 variants located within 100 kb upstream and downstream from 14 loci previously 
associated with ICS response were evaluated. After applying a Bonferroni-like correction for the 
number of variants analyzed within each genomic region, suggestive associations were observed 
for nine SNPs near three genomic regions: ALLC (min p-value = 4.69x10
-4 
for the SNP 
rs113903375), L3MBTL4-ARHGAP28 (min p-value = 1.57x10
-5 
for the SNP rs62081416), and 
ELMO2-ZNF334 (min p-value = 3.56x10
-4 
for the SNP rs2425845) (Table S6). However, applying 
a more restrictive correction for the total number of independent variants across all genomic 
regions (p ≤1.71x10-5 for 2,916 independent variants tested), only the association of rs62081416, 
located within the intergenic region of L3MBTL4 and ARHGAP28, was significantly associated 
with ICS response in admixed individuals (OR for A allele = 2.44, 95% CI: 1.63-3.65, p = 1.57x10
-
5
). 
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DISCUSSION 
In this study, we carried out the first GWAS of ICS response in Hispanic/Latino and African 
American children and young adults with asthma. After combining the association results from 
these two populations, 15 independent suggestive association signals were associated with asthma 
exacerbations despite use of ICS, and one of them showed evidence of nominal replication in 
Europeans. This SNP was also significantly associated with an increase in FEV1 after 6 weeks of 
treatment with ICS in one of the European studies where this outcome was measured. These results 
revealed for the first time the association of APOBEC3B and APOBEC3C genes with ICS response 
in asthmatic children and young adults. Additionally, we validated the association of the 
L3MBTL4-ARHGAP28 genomic region in admixed populations, which was previously described in 
a GWAS of ICS response in subjects of European descent.  
The APOBEC3B and APOBEC3C genes encode two members of the apolipoprotein B 
mRNA-editing catalytic polypeptide 3 (APOBEC3) family. APOBEC3 proteins are involved in 
RNA editing through the deamination of cytidine to uracil [47]. Their main function is related to 
innate immunity and are considered important restriction factors against a broad range of viruses 
[48]. However, APOBEC3 proteins are also involved in cellular processes related to mutagenic 
activity [49], including the development of several types of cancer, while APOBEC3B specifically 
has been associated with an increased risk of lung cancer [50]. 
We found that the A allele of rs5995653, located 5.8 kb from the 3’UTR of APOBEC3C, 
showed a protective effect against asthma exacerbations and was associated with improvement on 
FEV1 in patients treated with ICS. While no asthma-related functions have been attributed to any of 
the APOBEC3 flanking genes, evidence of high levels of RNA expression has been found in 
pulmonary fibroblasts for both genes [40-41]. Furthermore, the functional evidence found for 
rs5995653 suggests that this SNP plays a key role in regulating the expression of genes involved in 
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several cellular processes in the lung. Interestingly, respiratory viral infections are important risk 
factors for exacerbations in asthmatic children [51]. This fact is concordant with the consistent 
function of APOBEC3B and APOBEC3C as restrictors of viral infections, suggesting that the 
expression of these genes in pulmonary tissues could be involved in fighting against viral-induced 
asthma exacerbations in patients treated with ICS.  
Our study has several strengths. First, this is the largest meta-GWAS of ICS response with a 
discovery phase specifically focused on Hispanic/Latino and African American asthma patients, the 
minority ethnic groups most affected by asthma in the United States [4]. Admixed populations with 
African and Native American have been underrepresented in the asthma pharmacogenomic studies 
of ICS response [4]. Secondly, we identified a novel association shared among admixed and 
European populations, which could be also influential in other populations. Third, we validated the 
association of three genomic regions previously described in GWAS of ICS response in European 
and Asian populations [11, 13] and one of them was associated with an improvement in FEV1 after 
treatment with ICS in adults [11]. This evidence reinforces the validity of asthma exacerbations as 
a good measure of response to the asthma treatment with ICS. Finally, the fact that the intergenic 
region of L3MBTL4 and ARHGAP28 has been previously identified in adults could suggest the 
existence of common genetic markers of ICS response among adulthood and childhood asthma 
[13]. 
We recognize some limitations of our study. First, the most significant variant associated 
with ICS response in admixed and European populations did not reach genome-wide significance. 
This result was replicated in independent samples at nominal level, although it would not still be 
significant after a multiple comparison correction. Second, this study did not include a considerable 
larger sample size compared to the largest GWAS of ICS response published to date [17]. Third, 
even though the HRC reference panel is the largest catalogue of variants from the whole genome 
available to date [26], admixed populations with African and Native American ancestries are not 
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well represented. Fourth, asthma exacerbations were differentially defined in the European 
populations included in the replication phase. Nevertheless, this outcome was homogeneously 
defined in the studies included in the discovery phase, suggesting that the identified locus is 
robustly associated with asthma exacerbation across a range of definitions. Fifth, ICS response was 
evaluated as the presence or absence of asthma exacerbations in asthmatic patients with a self-
reported use of ICS, which might not correspond to compliance or changes with the asthma control 
therapy. For this reason, the association signal detected was followed up for replication using a 
quantitative measurement of ICS response, which was only available in one of the European 
populations. Additional studies should seek to validate the association signal when using change in 
FEV1 after the treatment with ICS as the response variable. Finally, functional evidence relating the 
intergenic region of APOBEC3B and APOBEC3C with ICS response in asthma patients was not 
directly assessed in this current study, since only experimental data available in public databases 
was queried. Therefore, in vitro experiments in relevant tissues and cell types for ICS response are 
needed to evaluate the functional roles of these loci in order to confirm their implication in this 
trait.  
In summary, our meta-GWAS in admixed children and young adults identified a novel 
association of genetic variants from the intergenic region of APOBEC3B and APOBEC3C as with 
ICS response in subjects with asthma. We also validated the association of one genomic region 
previously associated with ICS response. Our study demonstrates the advantages of including 
admixed populations in asthma pharmacogenomic studies of ICS response. 
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FIGURE LEGENDS 
 
Figure 1. Manhattan plot of association results of ICS response in the discovery phase. 
Association results are represented as -log10 p-value on the y-axis along the chromosomes (x-axis). 
The suggestive significance threshold for replication is indicated by the black line (p≤5x10-6). 
Figure 2. Regional plot of association results in the discovery phase for the APOBEC3B-
APOBEC3C intergenic region, which represents a novel association with ICS response. 
Statistical significance of association results (-log10 p-value) (y-axis) is represented by chromosome 
position (x-axis) for each SNP as a dot. A diamond represents the independent association signal 
with evidence of replication in Europeans (rs5995653) and the remaining SNPs are color-coded 
based on their LD with this SNP, indicated by pairwise r
2
 values for American populations from 
the 1KGP. 
Figure 3. Forest plot of association effect of rs5995653 across studies. Odds ratio (OR) for the 
effect allele (A) is shown for each study and after combining them by black boxes and a blue 
diamond. Black dash lines indicate the corresponding 95% Confidence Intervals (95% CI) for each 
individual study.  
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TABLES 
Table 1. Clinical and demographic characteristics of the admixed populations analyzed in the 
discovery phase. 
   
GALA II                                                   
(n = 854)  
SAGE                                                          
(n = 493) 
Gender (% male)  57.3  54.2 
Mean age ± SD (years)  12.1 ± 3.2  13.5 ± 3.4 
Ethnicity  Hispanic/Latino  African American 
Mean genetic ancestry (%)     
      African  13.6  79.4 
      European  51.5  20.6 
      Native-American  34.9  NA 
Asthma exacerbations in the last 12 
months (%) 
 66.4  51.9 
      Emergency asthma care (%)  56.6  43.2 
      OCS use (%)  40.2  29.4 
      Hospitalizations (%)  12.6  5.7 
SD: standard deviation; OCS: oral corticosteroids; NA: not available. 
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Table 2. Association results for the suggestive SNPs followed up for replication in European populations. 
      
Admixed populations (n=1,347) 
 
European populations 
 (n=1,697) 
SNP  Chr.a Positionb Nearest gene(s) A1/A2 
 
Freq.c 
 
OR (95% CI)d p-value 
 
Freq.c 
 
OR (95% CI)d p-value 
rs11121611 1 6367219 ACOT7 G/T 
 
0.201 
 
0.55 (0.43-0.70) 1.65 x 10-6 
 
0.062 
 
0.97 (0.61-1.56) 0.247 e 
rs35514893 6 15909525 DTNBP1-MYLIP T/C 
 
0.020 
 
0.36 (0.23-0.55) 2.86 x 10-6 
 
0.082 
 
0.73 (0.22-2.46) 0.613 
rs4897302 6 123886231 TRDN T/C 
 
0.505 
 
1.58 (1.31-1.91) 1.75 x 10-6 
 
0.221 
 
0.96 (0.81-1.13) 0.637 
rs61585310 7 104006510 LHFPL3 G/T 
 
0.796 
 
0.61 (0.49-0.75) 2.85 x 10-6 
 
0.763 
 
0.91 (0.74-1.11) 0.352 
rs7851998 9 126828514 LHX2-NEK6 A/G 
 
0.191 
 
0.56 (0.44-0.72) 3.97 x 10-6 
 
0.046 
 
0.83 (0.65-1.06) 0.132 
rs2125362 11 86167136 ME3 A/G 
 
0.684 
 
1.31 (0.68-2.56) 3.53 x 10-6 e 
 
0.750 
 
0.97 (0.82-1.16) 0.764 
rs450789 13 33578233 KL G/A 
 
0.334 
 
0.64 (0.53-0.77) 3.33 x 10-6 
 
0.271 
 
0.97 (0.83-1.15) 0.756 
rs12959468 18 15182381 ANKRD30B-ROCK1 A/G 
 
0.039 
 
0.39 (0.26-0.58) 2.99 x 10-6 
 
0.077 
 
1.39 (0.74-2.62) 0.309 
rs2278992 19 18095769 KCNN1 C/T 
 
0.176 
 
0.59 (0.47-0.74) 3.76 x 10-6 
 
0.151 
 
1.00 (0.81-1.24) 0.991 
rs6001366 22 39399941 APOBEC3B-APOBEC3C T/C 
 
0.079 
 
0.47 (0.35-0.65) 2.53 x 10-6 
 
0.064 
 
1.00 (0.72-1.38) 0.995 
rs5995653 22 39404249 APOBEC3B-APOBEC3C A/G   0.285 
 
0.66 (0.56-0.79) 4.80 x 10-6 
 
0.508 
 
0.76 (0.62-0.93) 7.52 x10-3 
 
aChromosome; bPositions based on GRCh37/hg19 build; cFrequency of the effect allele; dOdds ratio for the effect alleles (additive model); eRandom-effect model was 
applied since heterogeneity was found between admixed/European populations. A1: Effect allele; A2: Non-effect allele; CI: Confidence Interval.  
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